<DOC>
	<DOCNO>NCT00458861</DOCNO>
	<brief_summary>This Phase 2b study design evaluate efficacy safety BG9924 give subcutaneously ( SC ) versus placebo participant active rheumatoid arthritis ( RA ) previously inadequate response treatment anti-tumor necrosis factor ( anti-TNF ) therapy .</brief_summary>
	<brief_title>BG9924 Combination With Methotrexate Participants With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Diagnosis rheumatoid arthritis ( functional class I III ) least 6 month prior baseline Methotrexate ( 10 mg/week 25 mg/week ) &gt; 3 month prior Day 0 ( stable dose &gt; 4 week prior Day 0 ) Must inadequate response antiTNF therapy due inadequate efficacy Key Medical History Serious local infection systemic infection within 3 month Day 0 History ( Hx ) recurrent infection require oral parental antiinfective treatment Hx tuberculosis ( TB ) positive purify protein derivative ( PPD ) test screen period Laboratory Tests Clinically significant lab test screen ; Positive hepatitis C antibody hepatitis B screen NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Active Rheumatoid Arthritis ( RA )</keyword>
</DOC>